Commenting on the Group’s performance in Q1 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “During the first quarter, our Business EPS grew by 7.2%2. This strong performance was driven by Genzyme, our growth platforms3, and cost savings. This quarter also reflects the production recovery of Genzyme with the first shipment of Fabrazyme® produced in Framingham in March. In addition, we have submitted three new products to regulatory authorities, and released impressive clinical results for our anti-PCSK9 agent and for LemtradaTM at recent medical congresses. Although as expected, Plavix ® will lose exclusivity in May in the U.S., the strong underlying performance of the business is consistent with our medium term growth outlook”.
April 27, 2012